Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

319 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2020-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For the specific patient population studied receiving 5-Fluorouracil, epirubicin and cyclophosphamide - Docetaxel sequence (cumulative dose \<300 mg / m2), using a cryoprotection has never been assessed.

The effectiveness of cryoprotection of onycholysis secondary to Docetaxel is not well established in this population (breast cancer in the adjuvant setting) and is based solely on a publication (Scotté) that does not contain the same therapeutic modalities (dose significantly higher). The few studies available have heterogeneous populations, nonrandomized, retrospective or with a small sample.

By extension to what has been observed with higher cumulative doses of docetaxel, some teams offer mittens and booties chilled to their patients, a practice that is not the subject of a national consensus.

The investigators wish to accurately assess the effectiveness of mittens and slippers chilled, their tolerance and their observance because of weak data on this specific population in the literature.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer

NCT00925418

Breast Neoplasms Prostate Cancer Nail Diseases

COMPLETED PHASE3

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

NCT01243541

Chemotherapeutic Agent Toxicity Pain Peripheral Neuropathy +9 more

TERMINATED NA

The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer

NCT04558034

Cryotherapy Effect Peripheral Neuropathy Nail Toxicity

TERMINATED NA

Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion

NCT04215744

Breast Cancer

UNKNOWN NA

Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

NCT04256512

Breast Carcinoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard cryoprotection

Proposal helmet without mittens and booties

Group Type ACTIVE_COMPARATOR

cooling helmet

Intervention Type OTHER

Cryoprotection with mittens and booties

Standard cryoprotection with mittens and booties

Group Type EXPERIMENTAL

mittens and booties

Intervention Type OTHER

cooling helmet

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mittens and booties

Intervention Type OTHER

cooling helmet

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* upper age to 18 years
* mammary adenocarcinoma nonmetastatic and histologically proven
* wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500 or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++
* Patient with the capacity/faculties to understand a newsletter and sign an informed consent
* Patient receiving social coverage
* Patient who can be treated and followed in the center for a period of at least one year
* WHO scale 0 or 1

Exclusion Criteria

* Age below 18 years
* Diseases of the scalp or whatever hair-showing against helmet or alopecia
* Using pre nail resin before and per chemotherapy
* mammary adenocarcinoma stage IV
* Indication of docetaxel for cancer of another organ than breast
* Treatment processing or programmed during chemotherapy with an innovative molecule being evaluated
* Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.
* Uncontrolled severe arterial disease.
* Presence of a device\> grade 1 neuropathy before the start of chemotherapy
* Patient unable to submit the protocol followed for psychological, social, family or geographical
* Patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic
* Patient trust, guardianship, under legal protection measure, deprived of freedom
* Male
* Criteria for non randomization (before the first course of docetaxel) :

* Presence of peripheral neuropathy\> grade 1 after the first 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.
* Presence of a nail or skin toxicity\> grade 1 after 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No